Close Menu

Luminex

Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.

The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.

The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.

The assay is part of a respiratory testing menu that includes assays for Bordetella and Flu A/B & RSV, and NxTAG and Verigene respiratory pathogen panels.

Luminex said that its total sample-to-answer molecular product revenue of $11.9 million grew 55 percent from $7.7 million in the third quarter of 2016.

The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today. 

Luminex alleges that Curiox's objective has been to cobble together an unvalidated "Frankenstein-ish" system that fails at producing accurate test results. 

The firm said that prior to entering clinical trials, it also needs to reduce failure rates of a cassette that is part of the Verigene 2 test.

The firm said that it is delaying clinical trials prior to its FDA submission of Verigene 2 for several reasons, including reducing cassette failure rates.

The fourth test for which the firm has received regulatory clearance this year takes aim at a common microbial cause of healthcare-associated infections.

Pages

Wired reports on how genetic genealogy's use in forensics has exploded in the year since an arrest in the Golden State Killer case was made.

Retraction Watch reports that the increase in retracted papers at a journal is due to more resources there to tackle publication ethics.

New York City has settled with a forensic scientist who was fired after questioning a DNA testing approach used by the medical examiner's office, the New York Times reports.

In Nature this week: technique for measuring replication fork movement, WINTHER trial results, and more.